| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.29 | 0.03 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.36 | 0.04 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.061 | 0.04 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.04 |